Viridian Therapeutics prices public offering of common stock at $22 per share

Viridian Therapeutics has successfully priced its public offering of common stock at $22 per share, a move that reflects strong investor interest and confidence in the company's future. This offering is significant as it will provide the necessary capital for Viridian to advance its innovative therapies, potentially leading to breakthroughs in treatment options for patients. The positive reception of the offering indicates a robust market environment for biotech firms, which is encouraging for both investors and the industry.